KOE:475830

Orum Therapeutics, Inc. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:07 UTC

Last close

n/aKRW

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-178107.2%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-155682.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Growth is the furthest below its sector's middle: 0.05 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.00x

36.90x

-7.97x

0.00x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.00x
Its own average over 3 years, 52.12B.
Profit36.90x
Its own average over 4 years, -1.14B.
Free cash flow-7.97x
Its own average over 4 years, 4.60B.
Debt0.00x
Its own average over 4 years, 7.40B.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at 36.90 times.

Sales is 0.00 times its own 3-year average; Profit is 36.90 times its own 4-year average; Free cash flow is -7.97 times its own 4-year average; Debt is 0.00 times its own 4-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 3-year average0.0005
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 4-year average36.90
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 4-year average-7.97
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 4-year average0.002
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW